StockData
Boundless Bio, Inc. logo

Boundless Bio, Inc. (BOLD) stock

BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$2.40−0.01 (-0.41%)

Close on Nov 18, 2026Market cap $54.60MP/E –Yield –

Boundless Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Boundless Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$56.73M. For fiscal 2025 it was -$47.21M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$47.21M–
FY2024Dec 31, 2024-$63.38M–
FY2023Dec 31, 2023-$47.49M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.01M–
Q1 FY2026Mar 31, 2026-$14.98M–
Q4 FY2025Dec 31, 2025-$10.53M–
Q3 FY2025Sep 30, 2025-$10.21M–
Q2 FY2025Jun 30, 2025-$11.88M–
Q1 FY2025Mar 31, 2025-$14.59M–
Q4 FY2024Dec 31, 2024-$16.03M–
Q3 FY2024Sep 30, 2024-$13.75M–
Q2 FY2024Jun 30, 2024-$17.74M–
Q1 FY2024Mar 31, 2024-$15.86M–
Q4 FY2023Dec 31, 2023-$11.95M–
Q3 FY2023Sep 30, 2023-$12.34M–
Q2 FY2023Jun 30, 2023-$11.02M–
Q1 FY2023Mar 31, 2023-$12.18M–

More Boundless Bio figures

See a number that looks wrong?